retatrutide safety clinical trial UK Guide: Key Facts on the New Weight-Loss Drug retatrutide safety profile clinical trials

The half-life of semaglutide is approximately seven days, meaning the medication remains active in your system long enough to deliver consistent therapeutic effects before the next weekly dose

1 Prime Therapeutics (Prime) recently released its latest clinical insights report, Metabolic dysfunction-associated steatohepatitis (MASH) A new era in liver health, which shares the latest clinical considerations regarding treatment of MASH, potential implications of the GLP-1 approval for MASH and what payers and providers should know about its impact on the marketplace

JCO Clin

Why is hydration important on GLP-1 medications

When the body breaks down fat quickly, it can lead to an increase in uric acid levels

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction